Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

3q26 amplification is an effective negative triage test for LSIL: a historical prospective study.

Heitmann ER, Lankachandra KM, Wall J, Harris GD, McKinney HJ, Jalali GR, Verma Y, Kershnar E, Kilpatrick MW, Tsipouras P, Harper DM.

PLoS One. 2012;7(7):e39101. doi: 10.1371/journal.pone.0039101. Epub 2012 Jul 6.

2.

Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding.

Jalali GR, Herzog TJ, Dziura B, Walat R, Kilpatrick MW.

Am J Obstet Gynecol. 2010 Jun;202(6):581.e1-5. doi: 10.1016/j.ajog.2009.12.016. Epub 2010 Feb 20.

PMID:
20171606
3.

Role of chromosome 3q26 gain in predicting progression of cervical dysplasia.

Rodolakis A, Biliatis I, Symiakaki H, Kershnar E, Kilpatrick MW, Haidopoulos D, Thomakos N, Antsaklis A.

Int J Gynecol Cancer. 2012 Jun;22(5):742-7. doi: 10.1097/IGC.0b013e31825104bd.

PMID:
22635026
4.

Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy?

Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, Borgatta L, Buck H, Kramer L, Rubin R.

J Fam Pract. 1998 Feb;46(2):125-34.

PMID:
9487318
5.

Amplification of the 3q chromosomal region as a specific marker in cervical cancer.

Wright TC, Compagno J, Romano P, Grazioli V, Verma Y, Kershnar E, Tafas T, Kilpatrick MW.

Am J Obstet Gynecol. 2015 Jul;213(1):51.e1-8. doi: 10.1016/j.ajog.2015.02.001. Epub 2015 Feb 4.

PMID:
25659466
6.

Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.

Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, Prendiville WJ.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008054. doi: 10.1002/14651858.CD008054.pub2. Review.

PMID:
23543559
7.
8.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
9.

[Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].

Magnani C, Gillio Tos A, De Marco L, Calvia M, Cipelletti A, Bestagini P, Pagano E, Segnan N, Ronco G.

Epidemiol Prev. 2012 Mar-Apr;36(2):88-94. Italian.

PMID:
22706358
10.

Human papillomavirus test with cytology triage in organized screening for cervical cancer.

Veijalainen O, Kares S, Kujala P, Tirkkonen M, Vuento R, Kholová I, Luukkaala T, Osuala V, Mäenpää J.

Acta Obstet Gynecol Scand. 2016 Nov;95(11):1220-1227. doi: 10.1111/aogs.13013.

PMID:
27591407
11.

A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations.

ASCUS-LSIL Traige Study (ALTS) Group.

Am J Obstet Gynecol. 2003 Jun;188(6):1393-400.

PMID:
12824968
12.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
13.

Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).

Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; ALTS Group.

J Natl Cancer Inst. 2006 Jan 18;98(2):92-100.

PMID:
16418511
14.

Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS).

Walker JL, Wang SS, Schiffman M, Solomon D; ASCUS LSIL Triage Study Group.

Am J Obstet Gynecol. 2006 Aug;195(2):341-8.

PMID:
16890545
15.
16.

Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.

Pan QJ, Hu SY, Guo HQ, Zhang WH, Zhang X, Chen W, Cao J, Jiang Y, Zhao FH, Qiao YL.

Gynecol Oncol. 2014 May;133(2):172-9. doi: 10.1016/j.ygyno.2014.03.008. Epub 2014 Mar 11.

PMID:
24631450
17.

Repeat cytology and human papillomavirus screening strategies in detecting preinvasive cervical lesions.

Li K, Yin R.

Medicine (Baltimore). 2015 Feb;94(5):e435. doi: 10.1097/MD.0000000000000435.

18.

Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA.

Perez Castro S, Iñarrea Fernández A, Lamas González MJ, Sarán Diez MT, Cid Lama A, Alvarez Martín MJ, Pato Mosquera M, López-Miragaya I, Estévez N, Torres Piñón J, Oña Navarro M.

J Med Virol. 2013 Jun;85(6):1063-8. doi: 10.1002/jmv.23544.

PMID:
23588733
19.

Triage of women with low-grade cervical lesions--HPV mRNA testing versus repeat cytology.

Sørbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES.

PLoS One. 2011;6(8):e24083. doi: 10.1371/journal.pone.0024083. Epub 2011 Aug 30.

20.

Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL.

Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, Woodward L.

J Fam Pract. 1998 Feb;46(2):136-41.

PMID:
9487319

Supplemental Content

Support Center